COLARIS® is the most accurate, highest-quality genetic
test available to diagnose hereditary nonpolyposis colorectal
cancer (HNPCC). People with an HNPCC gene mutation have greater
than a 90 percent lifetime risk of developing some type of
cancer.28 These
individuals not only have an increased risk of colorectal
and endometrial cancers, but also other cancers listed below:
| Cancer Type |
Mutation
Carrier Risk1, 35 |
General
Population Risk |
| Colorectal |
Up to 82% |
2% |
| Endometrial |
Up to 71% |
1.5% |
| Stomach |
Up to 13% |
<1% |
| Ovarian |
Up to 12% |
1% |
*
Patients with HNPCC may also have a slightly elevated risk
of the following cancers when compared to the general population:
ureter/renal pelvis, biliary tract, small bowel, pancreas,
brain and sebaceous adenomas.
Individuals with HNPCC who have already been diagnosed
with cancer also have an increased risk of developing a second
cancer. In these patients, there is a 30 percent risk of
a second cancer developing within 10 years of initial diagnosis
and a 50 percent chance of a second cancer developing within
15 years of initial diagnosis.2, 20
» Managing Patients With HNPCC
A genetic test for hereditary nonpolyposis
colorectal cancer (HNPCC) |
 |
|
